uniQure (QURE) has drawn fresh attention after a sharp move in its share price over the past month, in contrast with a weaker performance over the past 3 months. Investors are weighing this swing against the company’s gene therapy pipeline and recent financial figures.
See our latest analysis for uniQure.
The recent 90.03% 30 day share price return, on top of a 10% 7 day move and 1.60% gain in the last session, contrasts with a 26.64% year to date share price decline and a 76% 1 year total shareholder return, hinting at shifting expectations around uniQure’s risk and long term potential.
If uniQure’s swing has your attention, it can be useful to see what else is moving in related areas and scan 37 healthcare AI stocks
So with uniQure’s share price rebounding after a tough year and analysts’ targets sitting well above the last close, should you see this as a mispriced gene therapy player, or assume the market is already factoring in future growth?
Most Popular Narrative: 55% Undervalued
With uniQure last closing at $17.16 against a narrative fair value of $37.84, the current price sits well below what this widely followed model implies.
The potential accelerated approval for AMT-130 in treating Huntington's disease could significantly boost future revenues as it would be one of the first disease-modifying treatments available for this condition.
Read the complete narrative. Read the complete narrative.
Curious how that gap between fair value and share price is justified? The narrative leans heavily on rapid revenue expansion, rising margins, and a richer future earnings multiple. The key details sit in how those pieces fit together over the next few years.
Result: Fair Value of $37.84 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on AMT-130 clearing demanding FDA requirements and on uniQure managing execution risks after the revenue move from US$8.5m to US$1.6m.
Find out about the key risks to this uniQure narrative.
Next Steps
The debate around uniQure’s risks and rewards is clearly divided. If this story feels time sensitive, check the data for yourself and weigh up the 1 key reward and 4 important warning signs.
Looking for more investment ideas?
If uniQure has sharpened your focus, do not stop here. Some of the most interesting opportunities start showing up when you compare it with different types of stocks.
- Target potential mispricings by scanning 62 high quality undervalued stocks that pair solid fundamentals with prices that sit below many investors’ radars.
- Build income resilience by reviewing 12 dividend fortresses that combine higher yields with balance sheets investors often look for when seeking ongoing payouts.
- Prioritise capital preservation by checking 67 resilient stocks with low risk scores that many investors use when they want stability to anchor the rest of their portfolio.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com